These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24788661)

  • 21. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
    Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
    AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
    Calcagno A; Gonzalez de Requena D; Simiele M; D'Avolio A; Tettoni MC; Salassa B; Orofino G; Bramato C; Libanore V; Motta I; Bigliano P; Orsucci E; Di Perri G; Bonora S
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1840-3. PubMed ID: 23380733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2.
    Reynes J; Cournil A; Peyriere H; Psomas C; Guiller E; Chatron M; Cristol JP; Badiou S
    AIDS; 2013 May; 27(8):1295-302. PubMed ID: 23925378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
    Viganò A; Zuccotti GV; Martelli L; Giacomet V; Cafarelli L; Borgonovo S; Beretta S; Rombolà G; Mora S
    Clin Drug Investig; 2007; 27(8):573-81. PubMed ID: 17638398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
    Dahlin A; Wittwer M; de la Cruz M; Woo JM; Bam R; Scharen-Guivel V; Flaherty J; Ray AS; Cihlar T; Gupta SK; Giacomini KM
    Pharmacogenet Genomics; 2015 Feb; 25(2):82-92. PubMed ID: 25485598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
    Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Punyawudho B; Pengsuparp T
    Antimicrob Agents Chemother; 2015; 59(6):3240-5. PubMed ID: 25801567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
    Giacomet V; Cattaneo D; Viganò A; Nannini P; Manfredini V; Ramponi G; Clementi E; Zuccotti GV
    Pediatr Infect Dis J; 2013 Oct; 32(10):e403-5. PubMed ID: 24067562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
    Rasch MG; Engsig FN; Feldt-Rasmussen B; Kirk O; Kronborg G; Pedersen C; Gerstoft J; Obel N
    Scand J Infect Dis; 2012 Sep; 44(9):689-96. PubMed ID: 22680981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
    Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
    AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
    Manosuthi W; Prasithsirikul W; Tantanathip P; Chimsuntorn S; Nilkamhang S; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):643-50. PubMed ID: 21706942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
    Van Laethem K; De Munter P; Schrooten Y; Verbesselt R; Van Ranst M; Van Wijngaerden E; Vandamme AM
    J Clin Virol; 2007 May; 39(1):43-7. PubMed ID: 17369083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
    Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Furrer H; Brinkman K; Hoek FJ; Abeling NG; Krediet RT; Reiss P;
    AIDS; 2011 Nov; 25(17):2149-55. PubMed ID: 21857491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.
    Cassetti I; Madruga JV; Suleiman JM; Etzel A; Zhong L; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(3):164-72. PubMed ID: 17621463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.